By revolutionizing wound-healing monitoring with a secure, collaborative application for caregivers, Pixacare aims to improve care for the 2.5 million people suffering from chronic wounds in France. 1 ] By strengthening city-hospital collaboration, the application aims to reduce hospitalization times and the frequency of hospital consultations, thereby cutting healthcare costs and improving patients' quality of life.
Initial study results are promising: remote wound monitoring with Pixacare could reduce healing time by 33%, cut follow-up consultations by 55% and reduce the cost per patient by 1,500 euros over six months[2].
With the ambition of becoming the European leader in AI-assisted scar monitoring, this new round of funding will support three strategic axes: commercial expansion in France, regulatory validation of wound analysis algorithms, and the financing of clinical studies to measure the medico-economic impact of remote monitoring with a view to its entry into common law and hence reimbursement by the French Assurance Maladie.
"We are proud to have attracted prestigious investment funds that believe in our vision, despite a difficult financing environment. This second round of financing marks the arrival of recognized players among our shareholders, a crucial step in propelling us towards achieving our ambitious objectives over the next three years. The expertise and international network of Elaia and Bpifrance are undeniable assets for a medtech company like ours, which aims to extend its impact well beyond national borders." Says Matis Ringdal, CEO and co-founder of Pixacare.
Céline Passedouet, Investment Director at Elaia, comments We are delighted to announce our investment in Pixacare. The company is positioned as a key player in the field of digital health, offering innovative technology for the analysis and monitoring of wound healing. Pixacare is meeting the challenges of securing medical data, improving patient care and strengthening city-hospital collaboration. We are confident in their ability to grow across Europe."
"After supporting Pixacare with convertible bonds as part of the French Tech Seed scheme, Bpifrance, on behalf of the French government, is proud to support its commercial acceleration and the pursuit of its technological innovations. Pixacare has all the ingredients to become the benchmark player in wound healing monitoring. Explains Eva Clerc, Senior Investment Director at Bpifrance. "We were won over by the novel user experience offered by the platform and its ability to improve the care pathway by creating value with all medical staff and the patient."
Initiated in 2019 by ProfessorFrédéric Bodin, a plastic surgeon at Strasbourg University Hospital, with the support of SATT Conectus and propelled by the momentum of its co-founders Matis Ringdal and Vincent Marceddu and its Semia incubator, Pixacare has rapidly gained momentum. The company made its mark on the French medical landscape, gaining the trust of prestigious university hospitals and Unicancer centers. Today, more than thirty healthcare establishments have signed up with Pixacare to secure photos and centralize the data essential for monitoring the healing of 70,000 patients.
Since its first fund-raising round of 2 million euros 2021, the company has consolidated its commitment to quality and compliance, affixing the CE mark for medical devices to the product, as well as obtaining ISO 13485 certification for its quality management system.
Pixacare's offices are located in the heart of Strasbourg on the premises of Nextmed, a European reference center for innovation in healthcare. The twenty-strong Pixacare team fuses technological and medical excellence to revolutionize wound-healing monitoring.
Find out more: pixacare.com
Elaia is a leading European private equity firm with a strong technological DNA. We invest in high-potential digital and deep-tech startups from the seed stage, and accompany them until they become world leaders. For 20 years, our commitment has been to deliver financial performance with strong values.
We are proud to have been the first professional investor in over 100 startups, including many success stories such as Criteo (Nasdaq), Orchestra Networks (acquired by Tibco), Volterra (acquired by F5), Mirakl (valued at $3.5 billion in Series E) and Shift Technology (valued at over $1 billion in Series D).
Find out more: elaia.com
Bpifrance finances companies - at every stage of their development - with credit, guarantees and equity capital. Bpifrance supports them in their innovation and international projects. Bpifrance also supports their export activities through a wide range of products. Consulting, university, networking and acceleration programs for start-ups, SMEs and ETIs are also part of the services offered to entrepreneurs.
Thanks to Bpifrance and its 50 regional offices, entrepreneurs benefit from a single, close and efficient contact to help them meet their challenges.
The 500 million euro French Tech Seed Fund is designed to support the fund-raising of innovative start-ups and VSEs less than 3 years old with technology-intensive innovations. A product of the Future Investment Program (PIA), now part of France 2030 and operated on behalf of the French government by Bpifrance, the fund relies on accredited business introducers to identify and qualify these start-ups, and put them in touch with private investors. These business introducers, who guarantee the technological validity of the project, will enable public investment, in the form of Convertible Bonds of up to 400 million euros, to complement the capital provided by private investors. A further 100 million euros are earmarked for equity investment in addition to the conversion of Convertible Bonds.
More information on : Bpifrance.fr
● Translates a dual ambition: to sustainably transform key sectors of our economy (energy, automotive, aeronautics and space) through technological innovation, and to position France not just as a player, but as a leader in the world of tomorrow. From fundamental research, to the emergence of an idea, to the production of a new product or service, France 2030 supports the entire innovation lifecycle, right through to industrialization.
● Is unprecedented in its scale: €54 billion will be invested to ensure that our companies, universities and research organizations can successfully make the transition to these strategic sectors. The aim is to enable them to respond competitively to the ecological and attractiveness challenges of the world to come, and to foster the emergence of future leaders in our sectors of excellence. France 2030 is defined by two cross-functional objectives: to devote 50% of its spending to decarbonizing the economy, and 50% to emerging, innovative players, with no spending that is detrimental to the environment (in line with the Do No Significant Harm principle).
● Will be implemented collectively: designed and deployed in consultation with economic, academic, local and European players to determine the strategic orientations and flagship actions. Project leaders are invited to submit their applications via open, demanding and selective procedures to benefit from government support.
● Managed by the Secrétariat Général pour l'Investissement on behalf of the Prime Minister, and implemented by the Agence de la Transition Ecologique (ADEME), the Agence Nationale de la Recherche (ANR), Bpifrance, Banque Publique d'Investissement and the Caisse des Dépôts et Consignations (CDC).
Further information: gouvernement.fr/secretariat-general-pour-l'-investissement-sgpi
Pixacare : Aurélie Garcin,CMO; +33 (0)7 55 50 39 46 ; aurelie.garcin@pixacare.com
Elaia: Louisa Mesnard, CMO; lmesnard@elaia.com
Bpifrance : Juliette Fontanillas, Media Relations Officer; +33(0)6 72 76 08 09 ; juliette.fontanillas@bpifrance.fr
[1] P. Y. Courcoux. Master 2 thesis, Ecole des Hautes Etudes en Santé Publique. Une filière de santé " plaie chronique " pour l'accompagnement des patients sur le territoires santé, quel intérêt de santé publique ? 2011.
[2] Study currently being published. Clinical and medico-economic benefits of remote monitoring of chronic wounds. Guillaume Maxantet co. Vascular Surgery Department, Haguenau Hospital.
